| Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects Y Yang, O Dukhanina, B Tang, M Mamura, JJ Letterio, J MacGregor, ... The Journal of clinical investigation 109 (12), 1607-1615, 2002 | 493 | 2002 |
| Artificial intelligence and machine learning in clinical development: a translational perspective P Shah, F Kendall, S Khozin, R Goosen, J Hu, J Laramie, M Ringel, ... NPJ digital medicine 2 (1), 69, 2019 | 361 | 2019 |
| Real-world data for clinical evidence generation in oncology S Khozin, GM Blumenthal, R Pazdur JNCI: Journal of the National Cancer Institute 109 (11), djx187, 2017 | 293 | 2017 |
| Developing and adopting safe and effective digital biomarkers to improve patient outcomes A Coravos, S Khozin, KD Mandl NPJ digital medicine 2 (1), 14, 2019 | 254 | 2019 |
| Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non–small-cell lung cancer: US Food and Drug … GM Blumenthal, SW Karuri, H Zhang, L Zhang, S Khozin, D Kazandjian, ... Journal of Clinical Oncology 33 (9), 1008, 2015 | 212 | 2015 |
| FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase–positive non–small cell lung cancer S Khozin, GM Blumenthal, L Zhang, S Tang, M Brower, E Fox, W Helms, ... Clinical cancer research 21 (11), 2436-2439, 2015 | 206 | 2015 |
| A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer RJ Kelly, A Thomas, A Rajan, G Chun, A Lopez-Chavez, E Szabo, ... Annals of oncology 24 (10), 2601-2606, 2013 | 165 | 2013 |
| US Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 … S Khozin, GM Blumenthal, X Jiang, K He, K Boyd, A Murgo, R Justice, ... The oncologist 19 (7), 774-779, 2014 | 143 | 2014 |
| US Food and Drug Administration approval summary: atezolizumab for metastatic non–small cell lung cancer C Weinstock, S Khozin, D Suzman, L Zhang, S Tang, S Wahby, ... Clinical Cancer Research 23 (16), 4534-4539, 2017 | 140 | 2017 |
| Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting … SD Griffith, M Tucker, B Bowser, G Calkins, C Chang, E Guardino, ... Advances in therapy 36, 2122-2136, 2019 | 127 | 2019 |
| Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial A Rajan, CA Carter, A Berman, L Cao, RJ Kelly, A Thomas, S Khozin, ... The lancet oncology 15 (2), 191-200, 2014 | 127 | 2014 |
| System and method for providing a multi-dimensional contextual platform for managing a medical practice NB Findlay, J Parkinson, S Khozin, S Ferguson, MP Roy, P Larouche, ... US Patent App. 12/468,563, 2010 | 116 | 2010 |
| Advantages of a truly open-access data-sharing model MM Bertagnolli, O Sartor, BA Chabner, ML Rothenberg, S Khozin, ... New England Journal of Medicine 376 (12), 1178-1181, 2017 | 111* | 2017 |
| Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer S Khozin, RA Miksad, J Adami, M Boyd, NR Brown, A Gossai, I Kaganman, ... Cancer 125 (22), 4019-4032, 2019 | 109 | 2019 |
| Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer GM Blumenthal, Y Gong, K Kehl, P Mishra-Kalyani, KB Goldberg, ... Annals of Oncology 30 (5), 830-838, 2019 | 101 | 2019 |
| Real-world evidence in support of precision medicine: clinico-genomic cancer data as a case study V Agarwala, S Khozin, G Singal, C O’Connell, D Kuk, G Li, A Gossai, ... Health affairs 37 (5), 765-772, 2018 | 100 | 2018 |
| Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations S Khozin, A Coravos Clin Pharmacol Ther 106 (1), 25-27, 2019 | 98 | 2019 |
| Characteristics of real‐world metastatic non‐small cell lung cancer patients treated with nivolumab and pembrolizumab during the year following approval S Khozin, AP Abernethy, NC Nussbaum, J Zhi, MD Curtis, M Tucker, ... The Oncologist 23 (3), 328-336, 2018 | 98 | 2018 |
| An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non–small-cell lung cancer M Stewart, AD Norden, N Dreyer, HJ Henk, AP Abernethy, E Chrischilles, ... JCO clinical cancer informatics 3, 1-15, 2019 | 95 | 2019 |
| Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer CA Carter, A Rajan, C Keen, E Szabo, S Khozin, A Thomas, C Brzezniak, ... Annals of Oncology 27 (4), 693-699, 2016 | 90 | 2016 |
